Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million.
Australian biotech Immutep's LAG-3 checkpoint inhibitor eftilagimod alpha (efti) may not be the first drug in the class to reach the market, but is a strong contender and, according to at l
GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.
Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform.
California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which uses "switchable" cells that aim to eliminate the life-threatening side-e